Stonebridge Capital Advisors’s ResMed RMD Stock Holding History

Stonebridge Capital Advisors’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2	Closed	–	–	1054
2022 Q1	$0	Hold	2	–	–	﹤0.01%	1096
2021 Q4	$1K	Hold	2	–	–	﹤0.01%	939
2021 Q3	$1K	Buy	+2	New	+$547	﹤0.01%	917
2019 Q4	–	Sell	-13	Closed	-$2K	–	909
2019 Q3	$2K	Hold	13	–	–	﹤0.01%	739
2019 Q2	$2K	Buy	+13	New	+$1.44K	﹤0.01%	786

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

Stonebridge Capital Advisors's RMD Position: Q2 2022 in Review

Stonebridge Capital Advisors sold out of ResMed (RMD) in Q2 2022, closing a stake of 2 shares.

Stonebridge Capital Advisors first reported a position in RMD in Q2 2019 and held it in 5 quarters. The position peaked at $2K in Q3 2019. 676 funds tracked by Wall St. Rank hold RMD as of Q2 2022.

Stonebridge Capital Advisors reported no remaining ResMed position as of Q2 2022 after selling out during the quarter.
Stonebridge Capital Advisors sold 2 ResMed shares in Q2 2022.
Stonebridge Capital Advisors first reported a position in ResMed in Q2 2019 and held it in 5 quarters.
Stonebridge Capital Advisors's ResMed position peaked at $2K in Q3 2019.
676 funds tracked by Wall St. Rank held ResMed as of Q2 2022.

Based on Stonebridge Capital Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.